Visit https://www.peervoice.com/KRF860 to view the entire programme with slides. After completing “Beyond HPIs for Advanced Basal Cell Carcinoma: Exploring the Clinical Implications of New Evidence”, participants will be able to: Identify the immunotherapies in late clinical development for the management of advanced basal cell carcinoma (aBCC); Describe emerging efficacy and safety data for systemic therapeutic strategies; and Appraise and translate the latest evidence on emerging immunotherapies as second-line systemic treatments for aBCC in patients with progressive disease.